A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Clinical trial NCT04446650 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04446650
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-12
- Primary completion
- 2023-10-05
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.